AngioDynamics (NASDAQ:ANGO) Hits New 1-Year High on Analyst Upgrade

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) reached a new 52-week high during mid-day trading on Thursday after HC Wainwright raised their price target on the stock from $16.00 to $19.00. HC Wainwright currently has a buy rating on the stock. AngioDynamics traded as high as $14.80 and last traded at $14.47, with a volume of 1374802 shares changing hands. The stock had previously closed at $13.00.

Several other research firms have also weighed in on ANGO. Zacks Research lowered AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Finally, Canaccord Genuity Group lifted their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.50.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on AngioDynamics and maintained a $19 price target, signaling confidence in the company’s longer-term upside despite ongoing losses. MarketBeat ANGO
• Positive Sentiment: An earlier report said AngioDynamics set a new 52-week high following an analyst upgrade, which likely reinforced bullish sentiment around the name. AngioDynamics Sets New 52-Week High Following Analyst Upgrade
• Neutral Sentiment: HC Wainwright cut several fiscal 2027 EPS estimates for AngioDynamics, including Q1, Q2, Q4, and full-year forecasts, reflecting a more cautious near-term earnings outlook. MarketBeat ANGO
• Neutral Sentiment: Despite the lower estimates, HC Wainwright still projects AngioDynamics will narrow losses over time, with FY2027 EPS estimated at ($0.27), close to the broader consensus of ($0.26). MarketBeat ANGO
• Negative Sentiment: A Seeking Alpha piece titled “AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)” suggests some analysts see limited upside after the recent run, which could temper enthusiasm. Seeking Alpha article

Institutional Trading of AngioDynamics

A number of hedge funds have recently made changes to their positions in ANGO. D.A. Davidson & CO. acquired a new stake in AngioDynamics during the 4th quarter valued at $1,751,000. Weber Capital Management LLC ADV purchased a new stake in AngioDynamics during the 4th quarter worth $17,978,000. Bastion Asset Management Inc. lifted its holdings in AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock worth $14,107,000 after buying an additional 194,822 shares in the last quarter. Armistice Capital LLC lifted its holdings in AngioDynamics by 3.9% in the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after buying an additional 64,000 shares in the last quarter. Finally, Royce & Associates LP boosted its position in AngioDynamics by 27.3% in the 4th quarter. Royce & Associates LP now owns 1,267,451 shares of the medical instruments supplier’s stock valued at $16,274,000 after buying an additional 272,091 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Trading Down 4.5%

The business’s 50-day simple moving average is $12.24 and its two-hundred day simple moving average is $11.35. The company has a market capitalization of $558.37 million, a PE ratio of -15.53 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts forecast that AngioDynamics, Inc. will post -0.27 EPS for the current year.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.